D-chiro-inositol (often shortened to DCI or “D-chiro”) is a naturally occurring compound that plays a key role in how your body responds to insulin. It belongs to the inositol family, a group of sugar-like molecules found in cell membranes throughout the body. Of the nine forms of inositol, D-chiro-inositol is the second most abundant in mammals, and it has gained attention primarily for its potential benefits in polycystic ovary syndrome (PCOS) and insulin resistance.
How D-Chiro-Inositol Works in the Body
D-chiro-inositol acts as a signaling molecule inside your cells, specifically in the chain of events that happens after insulin binds to a cell’s surface. When insulin arrives, it triggers the release of small molecules called inositol phosphoglycans from cell membranes. These molecules then carry the insulin signal deeper into the cell, activating enzymes that help store sugar as glycogen and burn glucose for energy in the mitochondria.
In practical terms, D-chiro-inositol helps your cells actually follow through on insulin’s instructions. Without enough of it, insulin can knock on the door, but the message doesn’t get passed along efficiently. This is one reason researchers have connected low D-chiro-inositol levels with insulin resistance, a condition where cells stop responding normally to insulin and blood sugar stays elevated.
Where It Comes From
Your body gets D-chiro-inositol in two ways: from food and by converting its more common sibling, myo-inositol, using specialized enzymes called epimerases. These enzymes are activated by insulin itself, which creates a feedback loop. When insulin resistance develops, epimerase activity drops in affected tissues, leading to lower D-chiro-inositol levels exactly where they’re needed most.
In the diet, buckwheat is the richest known source. Certain buckwheat cultivars contain around 7 mg per gram of seed, making it far more concentrated than other options. D-chiro-inositol also appears in legumes, squash, pumpkin, citrus fruits, grapes, and dandelion, though in smaller amounts.
The 40:1 Ratio With Myo-Inositol
Your blood naturally maintains a ratio of about 40 parts myo-inositol to 1 part D-chiro-inositol. This balance varies by tissue. The ovaries, for example, rely heavily on myo-inositol for egg development, while tissues involved in sugar storage (like muscle and liver) use more D-chiro-inositol. This ratio matters because supplementing with too much D-chiro-inositol relative to myo-inositol can shift the balance in ways that help some tissues but harm others.
This is sometimes called the “Unfer paradox”: D-chiro-inositol can improve systemic metabolic markers like blood sugar and insulin levels, but excess amounts in the ovaries may worsen the hormonal imbalances that drive abnormal steroid production in conditions like PCOS. Many supplement formulations now combine myo-inositol and D-chiro-inositol at a 40:1 ratio to mirror the body’s natural plasma balance.
D-Chiro-Inositol and PCOS
The connection between D-chiro-inositol and PCOS is where most of the clinical research has focused. A landmark study published in the New England Journal of Medicine gave 1,200 mg of D-chiro-inositol daily to women with PCOS for six weeks. The results were striking: 19 out of 22 women who took D-chiro-inositol ovulated, compared to just 6 out of 22 in the placebo group. Free testosterone levels dropped by more than half, falling from an average of 1.1 to 0.5 ng per deciliter.
Later research in insulin-resistant women confirmed similar patterns over longer treatment periods. After six months of supplementation, participants showed significant reductions in fasting blood sugar, insulin levels, BMI, and testosterone. Estradiol (a form of estrogen) increased, and markers of insulin resistance improved across the board. All participants in one retrospective study showed reduced insulin levels and improved insulin resistance scores.
Potential Downsides of High Doses
D-chiro-inositol is not without risks, particularly at higher doses taken over longer periods. One concerning finding involves menstrual regularity. In a study of insulin-resistant women taking D-chiro-inositol for six months, only 4 women had menstrual irregularities at the start of the study. By the end, 16 women reported oligomenorrhea (infrequent periods) or amenorrhea (absent periods). This is the opposite of what you’d expect from a treatment meant to restore ovulation.
This paradox likely ties back to the tissue-specific ratio issue. While D-chiro-inositol improves insulin sensitivity and lowers androgens systemically, excessive levels in the ovaries can disrupt the local hormonal environment needed for normal follicle development and ovulation. This is why most current guidance favors combination formulas rather than high-dose D-chiro-inositol alone.
Typical Supplement Doses
Clinical trials have used a wide range of D-chiro-inositol doses, from as little as about 28 mg per day (when combined with myo-inositol in a 40:1 ratio) up to 1,200 mg per day as a standalone supplement. The higher doses (600 to 1,200 mg) were used in earlier studies focused specifically on D-chiro-inositol alone. More recent trials tend to use lower doses of D-chiro-inositol paired with myo-inositol, typically 150 to 300 mg of D-chiro-inositol alongside 1,100 mg of myo-inositol daily.
What the Guidelines Say
Despite promising individual studies, the overall evidence base remains limited. A systematic review and meta-analysis conducted to inform the 2023 international evidence-based PCOS guidelines found that D-chiro-inositol showed potential benefits for ovulation and some metabolic measures, but the evidence was described as “limited and inconclusive.” The guidelines stopped short of a firm recommendation, instead suggesting that clinicians and patients weigh the uncertainty together with individual preferences when deciding whether to try inositol supplementation.
This doesn’t mean D-chiro-inositol is ineffective. It means the number and quality of large-scale trials haven’t yet reached the threshold needed for a strong clinical endorsement. Many women with PCOS report benefits, and the biological rationale is well-established. The gap is between promising mechanism-level science and the kind of large, long-term studies that would make the evidence definitive.